19-05-2025, 23:15

Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo

Notified -
Globe Newswire19-05-2025, 23:15
10-02-2025, 20:05

Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis

Notified -
Globe Newswire10-02-2025, 20:05
16-09-2024, 17:05

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Globe Newswire16-09-2024, 17:05